9月20日 Weida Tong:The FDA experience with emerging genomics technologies and biomarker development(生命科学系列学术报告)

时间:2018-09-10浏览:12设置


报告人简介

Dr. Tong is Director of Division of Bioinformatics and Biostatistics and Senior Biomedical Research Service (SBRS) at FDA’s National Center for Toxicological Research (NCTR/FDA). He has served science advisory board for several multi-institutional projects in Europe and USA. He also holds adjunct appointment at several universities. He is the founder and board chairperson of newly established international MAQC Society. His division at FDA is to develop bioinformatic methodologies and standards to support FDA research and regulation and to advance regulatory science and personalized medicine. The most visible projects from his group are (1) conducting the Microarray and Sequencing Quality Control (MAQC/SEQC) consortium to develop standard analysis protocols and quality control metrics for emerging technologies to support regulatory science and precision medicine; (2) development of liver toxicity knowledge base (LTKB) for drug safety; (4) in silico drug repositioning for the enhanced treatment of rare diseases; and (4) development of various tools such as ArrayTrackTM suite to support FDA review and research on pharmacogenomics. In addition, his group also specializes in molecular modeling and QSARs with specific interest in estrogen, androgen, and endocrine disruptor.  Dr. Tong has published more than 250 papers and book chapters.


返回原图
/